Results 21 to 30 of about 146,093 (222)

Platelet Aggregability in Patients with Hypertension Treated with Angiotensin II Type 1 Receptor Blockers

Journal of Atherosclerosis and Thrombosis, 2007
Cardiovascular events associated with hypertension often involve thrombosis. Increased platelet activity is one of the risk factors of cardiovascular diseases. Antithrombotic properties of antihypertensive agents are not fully characterized. Angiotensin II type 1 receptor blockers (ARBs) are widely used for the treatment of hypertension.
Yuki, Sato, Satoshi, Fujii, Shogo, Imagawa, Kazue, Ohmura, Yoshinori, Ohmura, Yasuhiro, Andoh, Jie, Dong, Naoki, Ishimori, Tomoo, Furumoto, Hiroyuki, Tsutsui   +9 more
openaire   +4 more sources

Polymorphisms of the angiotensin II type 1 receptor gene affect antihypertensive response to angiotensin receptor blockers in hypertensive Chinese

Genetics and Molecular Research, 2013
The renin-angiotensin-aldosterone system plays a key role in regulating blood pressure by maintaining vascular tone and the water/sodium balance. Many antihypertensive drugs target the renin-angiotensin-aldosterone system, but the effect differs considerably among hypertensive patients.
Hongjian Gong, X.L. Ma, B.X. Chen, Xinyun Xu, Q. Li, Chao Guo, Frank Du   +6 more
openalex   +3 more sources

Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers

Drug, Healthcare and Patient Safety, 2010
Elisabet Ekman1, Staffan Hägg2, Anders Sundström3, Viktoria Werkström11Regional Pharmacovigilance Unit, Clinical Pharmacology, Lund University Hospital, Lund, Sweden; 2Division of Clinical Pharmacology, Linköping ...
Elisabet Ekman, Staffan Hägg, Anders Sundström, et al   +3 more
doaj   +3 more sources

The Differential Effects of Angiotensin II Type 1 Receptor Blockers on Microalbuminuria in Relation to Low-Grade Inflammation in Metabolic Hypertensive Patients [PDF]

American Journal of Hypertension, 2007
Yuichiro Yano, Satoshi Hoshide, Joji Ishikawa, Chishio Noguchi, Daisuke Tukui, Takanori Hidaka, Masashi Tada, Yoshimasa Kanemaru, Ayako Yano, Shizukiyo Ishikawa   +9 more
openalex   +2 more sources

Combined Therapy With a Calcium Channel Blocker and an Angiotensin II Type 1 Receptor Blocker

The Journal of Clinical Hypertension, 2008
Fixed‐dosed combination regimens consisting of a calcium channel blocker and an angiotensin II type 1 receptor blocker represent a new addition to the available antihypertensive treatment options. Clinical trials demonstrate that both the dihydropyridine calcium channel blocker amlodipine and angiotensin II receptor blockers are effective agents for ...
G. Bakris
openaire   +4 more sources

The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes [PDF]

Diabetes Care, 2005
Effie L. Gillespie, C Michael White, Michael J. Kardas, Michael Lindberg, Craig I Coleman   +4 more
openalex   +2 more sources

Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC. [PDF]

Sci Rep, 2016
It has been shown that angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) can decrease tumor growth and tumor-associated angiogenesis and inhibit metastasis.
Miao L, Chen W, Zhou L, Wan H, Gao B, Feng Y.   +5 more
europepmc   +2 more sources

Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. [PDF]

Mol Clin Oncol, 2015
The local renin-angiotensin system promotes angiogenesis and vascular proliferation via expression of vascular endothelial growth factor or epidermal growth factor receptor.
Osumi H, Matsusaka S, Wakatsuki T, Suenaga M, Shinozaki E, Mizunuma N.   +5 more
europepmc   +2 more sources

Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Renin‐angiotensin aldosterone system (RAAS) inhibitor—COVID‐19 studies, observational in design, appear to use biased methods that can distort the interaction between RAAS inhibitor use and COVID‐19 risk. This study assessed the extent of bias
Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström   +3 more
doaj   +1 more source

Losartan improved hippocampal long‐term potentiation impairment induced by repeated LPS injection in rats

Physiological Reports, 2021
Cognitive impairment has been known as a common consequence of brain inflammation. Long‐term potentiation (LTP), the generally accepted cellular mechanism for memory formation in the mammalian brain, has been shown to be suppressed by inflammation ...
Mahmoud Hosseini, Hossein Salmani, Yousef Baghcheghi   +2 more
doaj   +1 more source